05 Jun 2023 Avacta Achieves Second Milestone in AffyXell Joint Venture Triggering Increased Equity Stake Investors | Therapeutics
01 Jun 2023 Avacta acquires Coris Bioconcept, adding a broad range of marketed professional-use rapid tests to the Group Diagnostics | Investors
27 Apr 2023 First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study Investors | Therapeutics
17 Apr 2023 Avacta Presents AVA3996 Pre-clinical Data at the American Association for Cancer Research Meeting Investors | Therapeutics
06 Apr 2023 Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study Investors | Therapeutics